Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Micro-RNA-125a mediates the effects of hypomethylating agents in chronic myelomonocytic leukemia

6 Jan 2021

Abstract excerpt

BACKGROUND: Chronic myelomonocytic leukemia (CMML) is an aggressive hematopoietic malignancy that arises from hematopoietic stem and progenitor cells (HSPCs). Patients with CMML are frequently treated with epigenetic therapeutic approaches, in particular the hypomethylating agents (HMAs), azacitidine (Aza) and decitabine (Dec). Although HMAs are believed to mediate their efficacy via re-expression of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to MicroRNA in disease regulation
Share to Myeloproliferative Neoplasms: Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33407852
DOI: 10.1186/s13148-020-00979-2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Micro-RNA-125a mediates the effects of hypomethylating agents in chronic myelomonocytic leukemiaPMID 33407852Read ↗

The double-edged sword of (re)expression of genes by hypomethylating agents: from viral mimicry to exploitation as priming agents for targeted immune checkpoint modulationSemantic proximity Read ↗

Multi-omics reveals azacitidine partially restores the hematopoiesis-supportive functions in mesenchymal stromal cells from patients with chronic myelomonocytic leukemiaSemantic proximity Read ↗

Emerging drugs for the treatment of chronic myelomonocytic leukemia.Semantic proximity Read ↗

Contribution of mutant HSC clones to immature and mature cells in MDS and CMML, and variations with AZA therapySemantic proximity Read ↗

Effects of Hypomethylating Agents on Gene Modulation in the Leukemic Microenvironment and Disease Trajectory in a Mouse Model of AMLSemantic proximity Read ↗

Genome-wide pharmacologic unmasking identifies tumor suppressive microRNAs in multiple myeloma.Semantic proximity Read ↗

DNA Hypermethylation of Myeloid Cells, A Novel Therapeutic Target in MDS and AMLSemantic proximity Read ↗

Hotspot DNMT3A mutations in Clonal Hematopoiesis and Acute Myeloid Leukemia sensitize cells to Azacytidine via viral mimicry responseSemantic proximity Read ↗

A clinical-molecular update on azanucleoside-based therapy for the treatment of hematologic cancersSemantic proximity Read ↗

MicroRNA-125b transforms myeloid cell lines by repressing multiple mRNASemantic proximity Read ↗

Mechanisms of Action of Hypomethylating Agents: Endogenous Retroelements at the EpicenterSemantic proximity Read ↗

Hypomethylating agents induce epigenetic and transcriptional heterogeneity with implications for AML cell self-renewalSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.